23Jun 2023
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants

Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants

Orforglipron (LY3502970), an oral, non-peptide GLP-1 receptor agonist, was evaluated for safety and efficacy in a Phase 1 study. Participants received single and multiple doses of orforglipron, experiencing gastrointestinal side effects. Pharmacokinetics showed dose proportionality, with a half-life of 25-68 hours. Orforglipron led to significant weight loss and improved glucose levels, supporting its potential as a once-daily oral treatment. Continued clinical development is warranted.

  • #endo-diabetology

Like

Save

Share